Quick Comparison

DermorphinThymosin Beta-4
Half-Life1-2 hours (more stable than endogenous opioid peptides)1-2 hours
Typical DosageNo established human dosing. Research use only. Extremely potent — microgram quantities produce significant pharmacological effects. Not intended for human administration.Loading: 750 mcg-2 mg subcutaneous two or three times weekly for 2-4 weeks. Maintenance: 750 mcg-2 mg subcutaneous once or twice weekly. Some protocols use higher loading doses for acute injuries.
AdministrationResearch use only (injection)Subcutaneous injection
Research Papers19 papers30 papers
Categories

Mechanism of Action

Dermorphin

Dermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is a naturally occurring opioid heptapeptide first isolated from the skin of South American phyllomedusid tree frogs (Phyllomedusa sauvagei) in 1981. It is remarkable for containing a D-amino acid (D-alanine at position 2), a feature extremely rare in naturally occurring animal peptides and previously thought to be exclusive to bacterial peptides. This D-amino acid substitution is the key to both its extraordinary potency and stability.

Dermorphin is a highly selective agonist of the μ-opioid receptor (MOR/OPRM1), binding with 30-40 times greater affinity than morphine. MOR is a Gi/o-coupled GPCR — upon activation, it inhibits adenylyl cyclase (reducing cAMP), opens G protein-coupled inwardly rectifying potassium channels (GIRK), and closes voltage-gated calcium channels. The net effect on neurons is hyperpolarization and reduced neurotransmitter release. In pain pathways, MOR activation in the dorsal horn of the spinal cord inhibits ascending nociceptive signals, while activation in the periaqueductal gray and rostral ventromedial medulla activates descending pain inhibition pathways. In the reward system, MOR activation in the ventral tegmental area disinhibits dopaminergic neurons projecting to the nucleus accumbens, producing euphoria.

The D-alanine at position 2 is critical because it prevents cleavage by aminopeptidases and dipeptidyl peptidases that would rapidly degrade an L-amino acid peptide. This resistance to enzymatic degradation gives dermorphin a significantly longer half-life than endogenous opioid peptides like enkephalins (which are degraded within seconds to minutes). Combined with its extreme MOR selectivity and potency, this stability makes dermorphin pharmacologically powerful but also highly dangerous — the same properties that make it effective for analgesia create significant potential for respiratory depression, physical dependence, and fatal overdose. Its notoriety stems primarily from illicit use in horse racing, where it was administered to racehorses as an undetectable analgesic/performance enhancer before specific assays were developed.

Thymosin Beta-4

Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide and the most abundant member of the beta-thymosin family. Despite its name (derived from its original isolation from thymus tissue), Tβ4 is expressed in virtually every nucleated cell in the body and is particularly concentrated in platelets, wound fluid, and developing tissues. TB-500 is the commercially available active fragment.

The primary molecular function is G-actin sequestration. Tβ4 binds globular actin (G-actin) monomers at a 1:1 stoichiometric ratio through a central actin-binding domain (LKKTET motif), maintaining a large intracellular pool of unpolymerized actin available for rapid mobilization. When cells need to migrate — as during wound healing, inflammation, or development — Tβ4 releases G-actin for polymerization into filamentous actin (F-actin) at the cell's leading edge. This dynamic actin cycling is the fundamental force-generating mechanism for cell migration.

Beyond actin regulation, Tβ4 has extensive signaling functions. It promotes angiogenesis by stimulating endothelial cell migration, tubule formation, and the expression of VEGF and angiopoietin-1. It reduces inflammation by modulating NF-κB signaling, decreasing production of TNF-α, IL-1β, and other pro-inflammatory mediators. In wound healing, Tβ4 upregulates laminin-5 production — a key component of the basement membrane that guides epithelial cell migration during wound re-epithelialization. It activates cardiac progenitor cells and promotes cardiomyocyte survival following ischemic injury, an effect that has generated significant interest for cardiac repair applications.

Tβ4 also promotes stem cell migration and differentiation through activation of the Akt cell survival pathway. It stimulates hair follicle stem cell migration and differentiation, which has been observed as increased hair growth in animal studies. The combination of cell migration, angiogenesis, anti-inflammation, stem cell activation, and extracellular matrix remodeling makes Tβ4 one of the most comprehensive endogenous healing molecules identified.

Risks & Safety

Dermorphin

Serious

extreme potency makes dosing errors potentially fatal, severe respiratory depression, high addiction and physical dependence potential, sedation and impaired consciousness.

Rare

respiratory arrest and death from overdose.

Thymosin Beta-4

Common

injection site irritation, headache, nausea, temporary fatigue.

Serious

may promote existing tumors by stimulating new blood vessel formation and cell movement, no long-term data on effects on tissue remodeling.

Rare

allergic reactions, localized infection.

Full Profiles